Holen Sie sich die Stockscreener-App
3.67
6.69%
0.23
Handel nachbörslich:
3.72
0.05
+1.36%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$3.44
Offen:
$3.47
24-Stunden-Volumen:
5.17M
Relative Volume:
0.93
Marktkapitalisierung:
$323.90M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.2378
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
+1.10%
1M Leistung:
-10.05%
6M Leistung:
-42.83%
1J Leistung:
-45.22%
1-Tages-Spanne:
$3.4286
$3.70
1-Wochen-Bereich:
$3.35
$3.70
52-Wochen-Spanne:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.67 | 303.60M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade) (NASDAQ:ALT) - Seeking Alpha
Altimmune (ALT) Stock Rises on FDA's Acceptance of Surrogate Endpoint - GuruFocus
Will Altimmune Inc. price bounce be sustainableBond Market & Consistent Profit Trade Alerts - Newser
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - PR Newswire
Using Python tools to backtest Altimmune Inc. strategiesPortfolio Risk Summary & Growth Focused Entry Point Reports - Newser
Altimmune Inc. stock volume spike explainedTrend Reversal & Accurate Entry/Exit Alerts - Newser
Top chart patterns to watch in Altimmune Inc.2025 Momentum Check & Weekly Breakout Watchlists - Newser
Contact The Gross Law Firm by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc.(ALT) - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, - GlobeNewswire
Altimmune to Participate in Upcoming Investor Conferences - The Manila Times
Late-Stage Biotech Altimmune Announces Triple Conference Presence: Wells Fargo, HC Wainwright, Morgan Stanley - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming DeadlinesALT - WV News
Levi & Korsinsky Moves to SueWallSt for Altimmune, Inc. Investors That Lost Money - Stockhouse
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Is Altimmune Inc. still worth holding after the dip2025 Growth vs Value & Low Risk Profit Maximizing Plans - Newser
Real time breakdown of Altimmune Inc. stock performanceJuly 2025 Recap & Free Technical Pattern Based Buy Signals - Newser
Class Action Filed Against Altimmune, Inc. (ALT)October 6, 2025 Deadline to Join – Contact Levi & Korsinsky - GlobeNewswire
Altimmune, Inc. Sued for Securities Law Violations - GlobeNewswire
Faruqi & Faruqi investigates potential claims against Altimmune, Inc. - AInvest
ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc. - PR Newswire
Will Altimmune Inc. continue its uptrend2025 Breakouts & Breakdowns & Weekly High Potential Stock Alerts - Newser
Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Altimmune wins FDA fast track status for alcohol use disorder therapy - MSN
Will Altimmune Inc. stock recover after recent dropQuarterly Market Summary & Precise Trade Entry Recommendations - Newser
Altimmune Inc (ALT) Stock: A Comprehensive 52-Week Review - investchronicle.com
ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Altimmune, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Altimmune (ALT) Gains FDA Fast Track for Alcohol Use Disorder Treatment - GuruFocus
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - MarketScreener
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) | ALT Stock News - GuruFocus
Altimmune's Pemvidutide Receives FDA Fast Track Designation for Alcohol Use Disorder Treatment - Quiver Quantitative
Trend analysis for Altimmune Inc. this weekMarket Activity Recap & Scalable Portfolio Growth Ideas - Newser
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Before October 6, 2025Contact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Altimmune, Inc. – Investors with Losses Encouraged to Contact Johnson Fistel - GlobeNewswire
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders to Contact the Firm for Information About Their Rights - PR Newswire
ALT LAWSUIT ALERT: The Gross Law Firm Notifies Altimmune, - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. LawsuitALT - PR Newswire
Altimmune Inc. stock trend outlook and recovery pathWeekly Trend Report & Low Drawdown Investment Strategies - Newser
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
8.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):